
Feb 13 (Reuters) - Sanofi SA SASY.PA:
PRESS RELEASE: UPDATE ON EXTRAINTESTINAL PATHOGENIC E. COLI VACCINE PHASE 3 CLINICAL STUDY
VACCINE CANDIDATE FAILS TO SHOW SUFFICIENT EFFICACY
NO SAFETY SIGNALS IDENTIFIED FOR E. COLI VACCINE CANDIDATE
E.MBRACE PHASE 3 STUDY DISCONTINUED
RECORDS $250 MILLION IMPAIRMENT CHARGE IN Q4 2024
FULL-YEAR IFRS EPS ADJUSTED TO €4.44 FROM €4.59
MAINTAINS 2025 FINANCIAL GUIDANCE
Source text: ID:nGNX6mXTG
Further company coverage: SASY.PA